Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 07 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

East–West gradient in the incidence of IBD in Europe

The latest issue of Gut investigates the East–West gradient in the incidence of IBD in Europe.

News image

The incidence of inflammatory bowel disease (IBD) is increasing in Eastern Europe.

The reasons for these changes remain unknown.

Dr Burisch and colleagues from Denmark investigated whether an East–West gradient in the incidence of IBD in Europe exists.

A prospective, uniformly diagnosed, population based inception cohort of IBD patients in 31 centres from 14 Western, and 8 Eastern European countries covering a total background population of approximately 10.1 million people was created.

One-third of the centers had previous experience with inception cohorts.

35% were diagnosed with Crohn's disease
Gut

Patients were entered into a low cost, web based epidemiological database, making participation possible regardless of socioeconomic status and prior experience.

The research team evaluated 1515 patients aged 15 years or older, of whom 35% were diagnosed with Crohn's disease, 54% with ulcerative colitis, and 11% with IBD unclassified (IBDU).

The team observed that the overall incidence rate ratios in all Western European centres were 1.9 for Crohn's disease, and 2.1 for ulcerative colitis compared with Eastern European centers.

The median crude annual incidence rates per 100,000 in 2010 for Crohn's disease were 7 in Western European centers, and 3 in Eastern European centers, for ulcerative colitis 11 and 4, respectively, and for IBDU 2 and 0, respectively.

In Western Europe, 92% of Crohn's disease, 78% of ulcerative colitis, and 74% of IBDU patients had a colonoscopy performed as the diagnostic procedure compared with 90%, 100% and 96%, respectively, in Eastern Europe.

The researchers found that 8% of Crohn's disease, and 1% of ulcerative colitis patients in both regions underwent surgery within the first 3 months of the onset of disease.

The team noted that 7% of Crohn's disease patients, and 3% of ulcerative colitis patients from Western Europe received biological treatment as rescue therapy.

Of all European Crohn's disease patients, 20% received only 5-aminosalicylates as induction therapy.

Dr Burisch's team comments, "An East–West gradient in IBD incidence exists in Europe."

"Among this inception cohort—including indolent and aggressive cases—international guidelines for diagnosis and initial treatment are not being followed uniformly by physicians."

Gut 2014; 63: 588-597
10 March 2014

Go to top of page Email this page Email this page to a colleague

 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 29 November 2016 
Treating Zenker's diverticulum
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us